Article Text

PDF
Review: depot antipsychotics may reduce risk of relapse compared with oral antipsychotics in people with schizophrenia

Statistics from Altmetric.com

Question

Question

Is risk of relapse reduced in patients with schizophrenia using depot antipsychotic drug regimens compared with oral drugs?

Outcomes

Primary outcome: risk of relapse. Secondary outcomes: rehospitalisation, non-adherence to drug regimen, discontinuation of treatment (any cause).

Methods

Design

Systematic review and meta-analysis.

Data sources

Eligible studies were identified through hand searches of Cochrane reviews of single depot antipsychotics. Update searches were carried out in the Cochrane Schizophrenia Group database in June 2009, and additional studies were identified by hand searching of reference lists, specific journal and conference proceedings, the ClinicalTrials.gov website and contact with manufacturers of depot drugs to identify further trial data.

Study selection and analysis

Studies were included if they were randomised controlled trials (RCT) comparing oral and depot drug regimens of antipsychotic medications in outpatients with schizophrenia or related disorders, with at least 1 year of follow-up. Studies in which fewer than 25% of participants were initially in inpatient settings were also deemed eligible. Studies were excluded if randomisation procedures were inadequate. Data extraction and bias assessment were performed by two reviewers. Meta-analysis was used to combine the results of eligible studies, and RR and numbers needed to treat …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.